ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements
Vijaypd Ceutical Limited intimated NSE of a board meeting on November 14, 2026 to consider unaudited half-yearly financial results for the period ended September 2026. The trading window stays closed until November 16, 2026.
Vijaypd Ceutical's board approved altering its Memorandum main object clause. It also fixed a postal ballot cut-off date and appointed a scrutinizer.
Vijaypd Ceutical Limited has appointed Finportal Investments Private Limited as its Investor Relations agency to provide advisory services effective October 5, 2026.
Vijaypd Ceutical Limited held its 2nd Annual General Meeting on September 30, 2026, to conduct ordinary and special business, including director appointments and various remuneration approvals.
VijayPD Ceutical entered a Technical Business Collaboration with Acute Research Private Limited for pharmaceutical R&D and process development support. No contract value is disclosed.
Vijaypd Ceutical Limited has appointed M/s. Nikunj Kanabar & Associates as the Secretarial Auditor for the financial year 2026-27.
Vijaypd Ceutical approved its 2nd Annual General Meeting notice, cut-off date, and the appointment of M/s. Nikunj Kanabar & Associates as Secretarial Auditor.
Vijaypd Ceutical Limited received an Expression of Interest from Squadron Pharmaceuticals LLP for API contract manufacturing. The exploratory association aims to expand export market presence.
Vijaypd Ceutical Limited has re-appointed M/s. Sodha & Associates as its Internal Auditors. The appointment is effective immediately for a twelve-month tenure.
VijayPD Ceutical Ltd reported revenue from operations of ₹47.6 Cr (-4.6% YoY) and net profit of ₹2.6 Cr (+44.4% YoY) for H2 FY26.
Vijaypd Ceutical Limited reported its audited financial results for the year ended March 31, 2026. The company achieved a consolidated net profit of ₹5.06 Crore.
Vijaypd Ceutical Limited signed a one-year MoU with Ann Finechem LLP for the bulk supply of APIs, including Lumefantrine and Artemether. The agreement, valued at approximately ₹30.20 Crore, establishes a framework for future purchase orders. This collaboration aims to enhance market expansion and ensure consistent supply through technical expertise.
Vijaypd Ceutical Limited submitted its Structured Digital Database (SDD) Compliance Certificate for the financial year ended March 31, 2026. The certificate, issued by Nikunj Kanabar & Associates, confirms the company has maintained an SDD in compliance with SEBI (Prohibition of Insider Trading) Regulations, with no non-compliances observed during the period.
Vijaypd Ceutical Limited submitted a compliance notification stating that Corporate Governance provisions under Regulation 27(2) are not applicable to the company. This exemption applies as the company is listed on the NSE EMERGE platform. Consequently, it is not required to submit a Corporate Governance Report for the quarter ended March 31, 2026.
Vijaypd Ceutical Limited is acquiring Siddharth Drugs Private Limited for ₹7.01 Crore in cash. The acquisition involves 5,00,000 equity shares at ₹140.2 per share and is expected to be completed by April 14, 2026. This strategic move allows the company to enter drug distribution and accelerate growth.
Vijaypd Ceutical Limited is acquiring a 100% stake in Siddharth Drugs Private Limited for ₹7.01 Crore in cash. The acquisition, expected to complete by April 14, 2026, allows the company to venture into drug distribution and accelerate growth.